Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration

Area of Science:

• Ophthalmology
• Medical Research

Background:

• Neovascular age-related macular degeneration (nv-AMD) is a leading cause of vision loss.
• Anti-vascular endothelial growth factor (VEGF) therapy is a standard treatment for nv-AMD.

Purpose of the Study:

• To review existing literature on the efficacy and safety of anti-VEGF treatment for nv-AMD beyond two years.
• To assess the long-term outcomes of sustained anti-VEGF inhibition in patients with nv-AMD.

Main Methods:

• Literature review of studies investigating long-term anti-VEGF treatment for nv-AMD.
• Analysis of patient data regarding visual acuity, treatment response, and adverse events.

Main Results:

• Limited studies exist for treatment durations exceeding two years, with small patient cohorts for four-year follow-ups.
• Most patients maintain visual acuity compared to baseline, though individual responses vary significantly.
• Approximately 20-30% show poor response, while 20% achieve inactive disease with good outcomes.
• Continuous treatment is necessary for the majority; long-term visual decline may reflect disease progression, but insufficient treatment is a possibility.
• Close monitoring for disease recurrence and fellow eye activity is crucial.
• Long-term anti-VEGF therapy appears well-tolerated with minimal ocular and systemic complications.

Conclusions:

• The majority of patients with nv-AMD can maintain visual acuity with long-term anti-VEGF treatment extending beyond two years.
• Sustained anti-VEGF inhibition is generally safe, with few reported ocular complications and systemic adverse events.